Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.22.9961

Clinical Significance of BCR-ABL Fusion Gene Subtypes in Chronic Myelogenous and Acute Lymphoblastic Leukemias  

Ye, Yuan-Xin (Department of Laboratory Medicine, West China Hospital, Sichuan University)
Zhou, Juan (Department of Laboratory Medicine, West China Hospital, Sichuan University)
Zhou, Yan-Hong (Department of Laboratory Medicine, West China Hospital, Sichuan University)
Zhou, Yi (Department of Laboratory Medicine, West China Hospital, Sichuan University)
Song, Xing-Bo (Department of Laboratory Medicine, West China Hospital, Sichuan University)
Wang, Jun (Department of Laboratory Medicine, West China Hospital, Sichuan University)
Lin, Li (Department of Laboratory Medicine, West China Hospital, Sichuan University)
Ying, Bin-Wu (Department of Laboratory Medicine, West China Hospital, Sichuan University)
Lu, Xiao-Jun (Department of Laboratory Medicine, West China Hospital, Sichuan University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.22, 2014 , pp. 9961-9966 More about this Journal
Abstract
Background: Some reports have suggested that chronic myeloid leukemia (CML) patients have a higher prevalence of M-bcr than acute lymphoblastic leukemia (ALL) patients, which show a higher prevalence of m-bcr. However, the relationship between BCR-ABL subtypes and progression of CML and ALL remains unclear. Materials and Methods: 354 CML chronic phase (CML-CP) patients, 26 CML blastic phase (CML-BP) patients and 72 ALL patients before treatment with BCR-ABL positive were recruited for blood routine examination and bone marrow smear cytology. Some 80 CML-CP and 32 ALL patients after imatinib (IM) treatment were followed-up for BCR-ABL relative concentrations detected after treatment for 3, 6 and 9 months and 1 year. Results: Before treatment, CML-CP patients showed lower BCR-ABL relative concentrations with a higher proportion of M-bcr (42.7%) compared to CML-BP and ALL patients while ALL patients had a higher BCR-ABL relative concentration with high expression of m-bcr (51.4%). Patients with M-bcr demonstrated higher WBC counts than those with m-bcr and the mixed group and higher PLT counts were noted in the CML-CP and ALL groups. After imatinib (IM) treatment, patients with m-bcr showed higher BCR-ABL relative concentrations in both CML-CP and ALL groups. Conclusions: This study identified the BCR-ABL gene as an important factor in CML and ALL cases. The M-bcr subtype was associated more with CML while the m-bcr subtype was associated more with ALL. Patients with m-bcr seem to have a poorer response to IM in either CML or ALL patients compared to M-bcr patients.
Keywords
BCR-ABL fusion gene; chronic myeloid leukemia; acute lymphoblastic leukemia;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 Al-Seraihy AS, Owaidah TM, Ayas M, et al (2009). Clinical characteristics and outcome of children with biphenotypic acute leukemia. Haematologica, 94, 1682-90.   DOI
2 Awan T, Iqbal Z, Aleem A, et al (2012). Five most common prognostically important fusion oncogenes are detected in the majority of Pakistani pediatric acute lymphoblastic leukemia patients and are strongly associated with disease biology and treatment outcome. Asian Pac J Cancer Prev, 13, 5469-75.   과학기술학회마을   DOI   ScienceOn
3 Bhatia P, Binota J, Varma N, et al (2012). A study on the expression of BCR-ABL transcript in mixed phenotype acute leukemia (MPAL) cases using the reverse transcriptase polymerase reaction assay (RT-PCR) and its correlation with hematological remission status post initial induction therapy. Mediterr J Hematol Infect Dis, 4, 2012024.   DOI
4 Cetin Z, Yakut S, Karadogan I, et al (2012). Aberrations of chromosomes 9 and 22 in acute lymphoblastic leukemia cases detected by ES-fluorescence in situ hybridization. Genet Test Mol Biomarkers, 16, 318-23.   DOI
5 Cho YJ, Zhang B, Kaartinen V, et al (2005). Generation of rac3 null mutant mice: role of Rac3 in Bcr/Abl-caused lymphoblastic leukemia. Mol Cell Biol, 25, 5777-85.   DOI
6 Chomel JC, Sorel N, Guilhot J, et al (2012). BCR-ABL expression in leukemic progenitors and primitive stem cells of patients with chronic myeloid leukemia. Blood, 119, 2964-65; author reply 2965-66.   DOI
7 Den Boer ML, van Slegtenhorst M, De Menezes RX, et al (2009). A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol, 10, 125-34.   DOI
8 Druker BJ, Guilhot F, O'Brien SG, et al (2006). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med, 355, 2408-17.   DOI   ScienceOn
9 Ernst T, Hochhaus A (2012). Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression. Semin Oncol, 39, 58-66.   DOI   ScienceOn
10 Fausel C (2007). Targeted chronic myeloid leukemia therapy: Seeking a cure. Am J Health Syst Pharm, 64, 9-15.
11 Gabert J, Beillard E, van der Velden VH, et al (2003). Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe against cancer program. Leukemia, 17, 2318-57.   DOI   ScienceOn
12 Gokbuget N, Stanze D, Beck J, et al (2012). Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood, 120, 2032-41.   DOI
13 Hanfstein B, Muller MC, Hehlmann R, et al (2012). Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia, 26, 2096-102.   DOI
14 Lee KH, Lee JH, Choi SJ, et al (2005). Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia, 19, 1509-16.   DOI   ScienceOn
15 Hehlmann R, Hochhaus A, Baccarani M (2007). Chronic myeloid leukaemia. Lancet, 370, 342-50.   DOI
16 Hunger SP (2011). Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia. Hematology Am Soc Hematol Educ Program, 2011, 361-5.   DOI
17 Killick S, Matutes E, Powles RL, et al (1999). Outcome of biphenotypic acute leukemia. Haematologica, 84, 699-706.
18 Li Y, Zou D, Zhao Y, et al (2010). Clinical characteristics and outcomes of adults with Philadelphia chromosome positive and/or bcr-abl positive acute lymphoblastic leukemia: a single center study from China. Leuk Lymphoma, 51, 488-96.   DOI
19 Lu X, Song X, Ye Y, et al (2011). Quantitative detection of BCRABL fusion gene and its application in monitoring chronic myeloid leukemia treatment. Mol Biol Rep, 38, 3101-5.   DOI
20 Marin D, Ibrahim AR, Lucas C, et al (2012). Assessment of BCRABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol, 30, 232-8.   DOI
21 Matutes E, Pickl WF, Van't Veer M, et al (2011). Mixedphenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood, 117, 3163-71.   DOI
22 Mulloy JC, Cancelas JA, Filippi MD, et al (2010). Rho GTPases in hematopoiesis and hemopathies. Blood, 115, 936-47.   DOI
23 Mizuta S, Matsuo K, Maeda T, et al (2012). Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR-ABL-positive ALL. Blood Cancer J, 2, 72.   DOI
24 Moorman AV, Harrison CJ, Buck GA, et al (2007). Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the medical research council (MRC) UKALLXII/ Eastern cooperative oncology group (ECOG) 2993 trial. Blood, 109, 3189-97.   DOI   ScienceOn
25 Mu Q, Ma Q, Wang Y, et al (2012). Cytogenetic profile of 1, 863 Ph/BCR-ABL-positive chronic myelogenous leukemia patients from the Chinese population. Ann Hematol, 91, 1065-72.   DOI
26 Ohanian M, Cortes J, Kantarjian H, Jabbour E (2012). Tyrosine kinase inhibitors in acute and chronic leukemias. Expert Opin Pharmacother, 13, 927-38.   DOI
27 Ohsaka A, Shiina S, Kobayashi M, et al (2002). Philadelphia chromosome-positive chronic myeloid leukemia expressing p190 (BCR-ABL). Intern Med, 41, 1183-7.   DOI
28 Press RD, Galderisi C, Yang R, et al (2007). A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinibinduced complete cytogenetic response. Clin Cancer Res, 13, 6136-43.   DOI
29 Soheila K, Hamid A, Farid Z, et al (2013). Comparison of univariate and multivariate gene set analysis in acute lymphoblastic leukemia. Asian Pac J Cancer Prev, 14, 1629-33.   과학기술학회마을   DOI   ScienceOn
30 Sabir N, Iqbal Z, Aleem A, et al (2012). Prognostically significant fusion oncogenes in Pakistani patients with adult acute lymphoblastic leukemia and their association with disease biology and outcome. Asian Pac J Cancer Prev, 13, 3349-55.   과학기술학회마을   DOI   ScienceOn
31 Tripathi AK, Kumar A, Ramaswamy A (2011). Total Leukocyte counts and the requirement of dose reduction due to cytopenias as prognostic indicators affecting response to imatinib in chronic myeloid leukemia. Indian J Hematol Blood Transfus, 27, 7-13.   DOI
32 Uchida N, Hanawa H, Dan K, et al (2009). Leukemogenesis of b2a2-type p210 BCR/ABL in a bone marrow transplantation mouse model using a lentiviral vector. J Nippon Med Sch, 76, 134-47.   DOI
33 Wang Y, Gu M, Mi Y, et al (2011). Clinical characteristics and outcomes of mixed phenotype acute leukemia with Philadelphia chromosome positive and/or bcr-abl positive in adult. Int J Hematol, 94, 552-5.   DOI
34 Weinberg OK, Arber DA (2010). Mixed-phenotype acute leukemia: historical overview and a new definition. Leukemia, 24, 1844-51.   DOI
35 Yanada M, Takeuchi J, Sugiura I, et al (2008). Karyotype at diagnosis is the major prognostic factor predicting relapsefree survival for patients with Philadelphia chromosomepositive acute lymphoblastic leukemia treated with imatinibcombined chemotherapy. Haematologica, 93, 287-90.   DOI
36 Yeung DT, Hughes TP (2012). Therapeutic targeting of BCR-ABL: prognostic markers of response and resistance mechanism in chronic myeloid leukaemia. Crit Rev Oncog, 17, 17-30.   DOI